General
Showing 1873–1888 of 1897 results
-
Article: Vascular safety profile of new generation BCR-ABL tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia
€2.42 Add to cart -
Article: Venetoclax-rituximab induces deep responses in relapsed CLL
€2.42 Add to cart -
Article: Venetoclax, the first available bcl-2 antagonist for chronic lymphocytic leukaemia
€2.42 Add to cart -
Article: Venetoclax, the first available bcl-2 antagonist for chronic lymphocytic leukaemia
€2.42 Add to cart -
Article: VENOUS THROMBOEMBOLISM
€2.42 Add to cart -
Article: Volume 6, Issue 1, February 2012
€2.42 Add to cart -
Article: Von Willebrand factor and ADAMTS13: new players in ischemia/reperfusion injury
€2.42 Add to cart -
Article: VON WILLEBRAND FACTOR: A NEW FLOW MARKER IN CARDIOVASCULAR PATHOLOGY
€2.42 Add to cart -
Article: Waldenstrom’s macroglobulinaemia: Belgian Hematology Society guidelines
€2.42 Add to cart -
Article: What about oligometastatic therapy in prostate cancer?
€2.42 Add to cart -
Article: What about oligometastatic therapy in prostate cancer?
€2.42 Add to cart -
Article: What About Oligometastatic Therapy In Prostate Cancer? Special,
€2.42 Add to cart -
Article: What can the tumour microenvironment tell us?
€2.42 Add to cart -
Article: What can the tumour microenvironment tell us?
€2.42 Add to cart -
Article: What do we still need to know about the treatment of RCC?
€2.42 Add to cart -
Article: What do we still need to know about the treatment of RCC?
€2.42 Add to cart
